Key Highlights: Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline data expected mid-2025 (FDA FTD). ivonescimab outperforms pembrolizumab in Phase III study for first-line PD-L1+ NSCLC: mPFS...
Hence then, the article about akeso s 2024 results strengthening global competitiveness and transforming the treatment landscape with bispecific antibodies was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies )
Also on site :
- Record-Setting Falcon 9 Launch from Vandenberg SFB Scheduled for Late Monday into Early Tuesday
- Ree Drummond Started a Blog About Life on an Oklahoma Ranch in 2006; 20 Years Later, She Has a Food Network Empire and a Retail Brand at Walmart
- Iran war live: Iran says US ‘not serious’ about talks; ship ablaze off Iraq